Fig. 1. Effect of different doses of aqueous extract of Folk Recipe (100, 200, 300 mg/kg) on blood glucose levels at different time intervals in normal rabbits

Test drugs: significant from normal control, * P < 0.05; ** P < 0.001

Mean ± S.E.M = Mean values ± Standard error of means of six experiments

3.1 Subheading Subheading (ARIAL, BOLD, 11 FONT, LEFT ALIGNED) - second level heading.

3.1.1 Sub-subheading (ARIAL, BOLD, 10 FONT, LEFT ALIGNED, underlined)- third level heading.

3.1.1.1 Sub-sub-subheading(ARIAL, ITALICS, BOLD, 10 FONT, LEFT ALIGNED) - fourth level heading.]

4. Conclusion

[This should briefly state the major findings of the study. If you are using copy-paste option then select ‘match destination formatting’ in paste option OR use ‘paste special’ option and select ‘unformatted Unicode text’ option]

AcknowledgEments

A brief acknowledgement section may be given after the conclusion section just before the references. The acknowledgments of people who provided assistance in manuscript preparation, funding for research, etc. should be listed in this section. All sources of funding should be declared as an acknowledgement. Authors should declare the role of funding agency, if any, in the study design, collection, analysis and interpretation of data; in the writing of the manuscript. If the study sponsors had no such involvement, the authors should so state.

Competing interests

Declaration of competing interest should be placed here. All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If no such declaration has been made by the authors, SDI reserves to assume and write this sentence: “Authors have declared that no competing interests exist.”.

Authors’ Contributions

Authors may use the following wordings for this section: “ ‘Author A’ designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. ‘Author B’ and ‘Author C’ managed the analyses of the study. ‘Author C’ managed the literature searches…… All authors read and approved the final manuscript.”

Consent (where ever applicable)

No manuscripts will be peer-reviewed if a statement of patient consent is not presented during submission (wherever applicable).

This section is compulsory for medical journals. Other journals may require this section if found suitable. It should provide a statement to confirm that the patient has given their informed consent for the case report to be published. Journal editorial office may ask the copies of the consent documentation at any time.

Authors may use a form from their own institution or SDI Patient Consent Form 1.0. It is preferable that authors should send this form along with the submission. But if already not sent during submission, we may request to see a copy at any stages of pre and post publication.

If the person described in the case report has died, then consent for publication must be collected from their next of kin. If the individual described in the case report is a minor, or unable to provide consent, then consent must be sought from their parents or legal guardians.

Authors may use the following wordings for this section: "All authors declare that ‘written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal."

Ethical approval (where ever applicable)

This section is compulsory for medical journals. Other journals may require this section if found suitable. If human subjects are involved, informed consent, protection of privacy, and other human rights are further criteria against which the manuscript will be judged. It should provide a statement to confirm that the authors have obtained all necessary ethical approval from suitable Institutional or State or National or International Committee. This confirms either that this study is not against the public interest, or that the release of information is allowed by legislation.

All manuscripts which deal with animal subjects must be approved by an Institutional Review Board (IRB), Ethical Committee, or an Animal Utilization Study Committee. , and this statement, and approval number, must accompany the submission. If required, author should be ready to submit a scanned copy of the IRB or Ethical Committee Approval at any stage of publication (Pre of post publication stage). The manuscript should contain information about any post-operative care and pain management for the animals.

For manuscripts involving animal experiments, Authors may use the following wordings for this section “All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee”

All manuscripts which deal with the study of human subjects must be accompanied by Institutional Review Board (IRB) or Ethical Committee Approval, or the national or regional equivalent. The name of the Board or Committee giving approval and the study number assigned must accompany the submission. If required, author should be ready to submit a scanned copy of the IRB or Ethical Committee Approval at any stage of publication (Pre of post publication stage).

For manuscripts involving human experiments, Authors may use the following wordings for this section: “All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.”

References

References must be listed at the end of the manuscript and numbered in the order that they appear in the text. Every reference referred in the text must also present in the reference list and vice versa. In the text, citations should be indicated by the reference number in brackets [3].

Only published or accepted manuscripts should be included in the reference list.

Articles submitted for publication, unpublished findings and personal communications should not be included in the reference list but may be mentioned in the text (e.g., T Nelson, Purdue University, USA, Unpublished results or personal communication). Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, obtain written permission and confirmation of accuracy from the source of a personal communication. Unpublished result which has been accepted for publication in any journal should be cited as "in press".

Journal name abbreviations should be those found in the NCBI databases (Link: http://www.ncbi.nlm.nih.gov/nlmcatalog/journals).

All references should follow the following style:

Reference to a journal:

For Published paper:

1. Hilly M, Adams ML, Nelson SC. A study of digit fusion in the mouse embryo. Clin Exp Allergy. 2002;32(4):489-98.

Note: List the first six authors followed by et al.

Note: Use of a DOI number for the full-text article is encouraged. (if available).

Note: Authors are also encouraged to add other database's unique identifier (like PUBMED ID).

For Accepted, unpublished papers.

Same as above, but “In press” appears instead of the page numbers.

1. Saha M, Adams ML, Nelson SC. Review of digit fusion in the mouse embryo. J Embryol Exp Morphol. 2009;49(3): (In press).

Note: List the first six authors followed by et al.

Note: Use of a DOI number is encouraged (if available).

Note: Authors are also encouraged to add other database's unique identifier (like PUBMED ID).

For Articles not in English

Forneau E, Bovet D. Recherches sur l'action sympathicolytique d'un nouveau dérivé du dioxane. Arch Int Pharmacodyn. 1933;46:178-91. French.

Reference to a book:

Personal author(s)

Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Edinburgh: Churchill Livingstone; 2003.

Editor(s) or compiler(s) as authors

Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, editors. The Merck manual of diagnosis and therapy. 18th ed. Whitehouse Station (NJ): Merck Research Laboratories; 2006.

Authored chapter in edited publication

Glennon RA, Dukat M. Serotonin receptors and drugs affecting serotonergic neurotransmission. In: Williams DA, Lemke TL, editors. Foye's principles of medicinal chemistry. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.

Reference to Web-resource or Electronic articles.

Hugo JT, Mondal SC. Parallels between tissue repair and embryo morphogenesis: a conceptual framework. Global Health. 2006;16:4. Accessed 29 March 2012.

Available: http://www.globalizationandhealth.com/content/1/1/14.

Anonymous. Parallels between tissue repair and embryo morphogenesis: a conceptual framework. Global Health. 2006;16:4. Accessed 29 March 2012.

Available: http://www.globalizationandhealth.com/content/1/1/14.

Date: 2016-03-03; view: 708